VICHEM CHEMIE KUTATO KFT
Desconocido
NeoVasculoStop: NATURAL INTRAOCULAR PHOTOACTIVATION OF COMPOUNDS TO FIGHT RETINOPATHIES
VICHEM CHEMIE KUTATO KORLATOLT FELELOSSEGU TARSASAG
participó en un
HORIZON EUROPE:
HORIZON-EIC-2021-PATHFINDEROPEN-01
Retinopathies constitute an extreme societal and socioeconomic burden that is expected to increase with an aging population and the increase...
2022-03-28 - 2026-02-28 | Financiado
2022-03-28 - 2026-02-28 | Financiado
PRIMES: PRIMES Protein interaction machines in oncogenic EGF receptor signalling
VICHEM CHEMIE KUTATO KORLATOLT FELELOSSEGU TARSASAG
participó en un
FP7:
PRIMES focuses on the role of protein interactions to assemble dynamic molecular machines that receive and process information to coordinate...
Financiado
Financiado
DIVINOCELL: Exploiting Gram negative cell division targets in the test tube to obtain anti microbial compounds
VICHEM CHEMIE KUTATO KORLATOLT FELELOSSEGU TARSASAG
participó en un
FP7:
The DIVINOCELL project will identify novel Gram-negative targets by exploiting the components of the divisome, their activities and interact...
Financiado
Financiado
LUNGTARGET: New approaches for the targeted therapy of Non Small Cell Lung Cancer
VICHEM CHEMIE KUTATO KORLATOLT FELELOSSEGU TARSASAG
participó en un
FP7:
Lung cancer is the most common cancer fatality in Europe (335000 deaths/yr). Non-small cell lung cancer (NSCLC) consists 85% of the cases, w...
Financiado
Financiado
NOPERSIST: Novel strategies for the prevention and control of persistent infections
VICHEM CHEMIE KUTATO KORLATOLT FELELOSSEGU TARSASAG
participó en un
FP7:
Persistent infections such as HIV, tuberculosis´(TB) in humans and para-tuberculosis (ParaTB)-, mycoplasma- and Haemophilus-infections in fa...
Financiado
Financiado
MM4TB: More Medicines for Tuberculosis
VICHEM CHEMIE KUTATO KORLATOLT FELELOSSEGU TARSASAG
participó en un
FP7:
The More Medicines for Tuberculosis (MM4TB) consortium evolved from the highly successful FP6 project, New Medicines for TB (NM4TB), that de...
Financiado
Financiado
ANTIFLU: Innovative anti influenza drugs excluding viral escape
VICHEM CHEMIE KUTATO KORLATOLT FELELOSSEGU TARSASAG
participó en un
FP7:
ANTIFLU is to develop innovative drugs against influenza virus infections based on a novel
concept that precludes the development of viral r...
Financiado
Financiado
OPTATIO: OPtimizing TArgets and Therapeutics In high risk and refractOry Multiple Myeloma
VICHEM CHEMIE KUTATO KORLATOLT FELELOSSEGU TARSASAG
participó en un
FP7:
Multiple Myeloma (MM) is an incurable disease with rapidly growing prevalence and poor prognosis. Consequently, it is the goal of the OPTATI...
Financiado
Financiado
TARKINAID: Targeting Src family tyrosine kinases in chronic autoimmune and inflammatory diseases
VICHEM CHEMIE KUTATO KORLATOLT FELELOSSEGU TARSASAG
participó en un
FP7:
The project aims to develop novel inhibitors of chronic autoimmune and inflammatory diseases by targeting members of the Src tyrosine kinase...
Financiado
Financiado
* No se disponen de datos de la empresa actual.